Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C Oliva
Preliminary Safety Data of Preoperative Chemotherapy Plus Trastuzumab, Lapatinib or Both in HER2-positive Operable Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
Related publications
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
Oncologist
Cancer Research
Medicine
Oncology
Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
Frontiers in Oncology
Cancer Research
Oncology
Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib
AboutOpen
Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer
Journal of Cancer Research and Clinical Oncology
Medicine
Cancer Research
Oncology
Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine
Cancer Management and Research
Oncology
HER2-positive Breast Cancer With Brain Metastasis, Long Responder to Lapatinib Therapy
AboutOpen
Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer
Biochimica et Biophysica Acta - Reviews on Cancer
Cancer Research
Oncology
Genetics
Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells With Primary Trastuzumab Resistance
Anti-Cancer Agents in Medicinal Chemistry
Cancer Research
Molecular Medicine
Pharmacology
